CTRI/2021/02/031142已完成2 期
A Randomized Placebo Controlled double blind, double dummy, parallel arm study to assess the comparative efficacy of three Turmeric-Boswellia formulations in Adult Subjects with Exercise Induced Acute Musculoskeletal Pain - MSP200
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Adult subjects, Male or female between 18-65 years of age.
- •2. A score of 5 or above on the NRS (at rest)
- •3. Subjects having Exercise Induced Acute Musculoskeletal Pain which occurred within 24 hours before presentation e.g. musculoskeletal injuries, myalgia, neck pain, limb pain, low back pain, joint pain, widespread musculoskeletal pain, painful uncomplicated acute soft tissue injury of the upper or lower extremity, including acute injuries of ligaments, tendons, or muscles (including Grade 1 sprain or strain), not requiring admittance to hospital.
- •4. Willing to give voluntary informed consent.
排除标准
- •Subject with acute muscle spasms who need parenteral therapy, surgery or hospital admission for management, painful uncomplicated acute soft tissue injury of the upper or lower extremity, including acute injuries of ligaments, tendons, or muscles.
- •2. Subjects with Grade 2 & 3 sprain or strain.
- •3. Subjects with known history of osteoarthritis and rheumatoid arthritis.
- •4. Subjects with uncontrolled hypertension (Diastolic blood pressure more than or equal to 110 mmHg and/or systolic blood pressure; more than or equal to 180 mmHg).
- •5. Subjects with open wounds infected skin or other conditions of broken skin, skin affected by infection with inflammations at the site of proposed action.
- •6. Subjects underlying dermatitis or dermatosis associated with the injury.
- •7. Use of any oral or topical analgesic, antipyretic, sedative, anti-inflammatory, muscle relaxants or any other oral or topical medications which in the opinion of the investigator would influence the conduct and outcomes of the study.
- •8. Prior use within 1 week of study any Ayurvedic, siddha, Unani or proprietary products for pain and inflammation.
- •9. Any kind of neuralgic pain, headache and/or chronic pain
- •10. Previous adverse reaction or known allergy to herbal, NSAID, steroids or any other severe food allergies.
- •11. A known pregnancy or lactation
- •12. Previous history of gastro-intestinal hemorrhage or perforation, active or recurrent peptic ulceration or peptic bleeding.
- •13. Subjects who are severe smokers (more than 2 packs/ day) and drinkers (more than 14 Pegs / week or more than 3 pegs / day)
- •14. Received an investigational or product or participated in an investigational study within a period of 30 days prior to receiving study medication.
- •15. Scheduled elective surgery or other invasive procedures during the period of study participation.
- •16. Subjects with a history of diabetes, cardiovascular, renal, pulmonary, endocrine, or neurological disorders, ulcers, dermatologic disorders, autoimmune diseases an active infectious disease (HBV, HCV, HIV) which in the opinion of the investigator would influence the conduct and outcomes of the study.
- •17. A current diagnosis or a history of relevant depressive episodes or of panic attacks, psychosis, bipolar or eating disorders.
研究者
相似试验
已完成
4 期
Sttudy to evaluate the efficacy and safety of KSM- 66 Ashwagandha on Subclinical Hypothyroidism patientsCTRI/2016/05/006903Shri Karthikeya Pharma50
尚未招募
不适用
Is use of combination of Acitretin capsule and topical triamcinolone gel better than triamcinolone gel alone in treatment of lichen planus of mouth.CTRI/2018/11/016448PGIMER
尚未招募
3 期
To evaluate the efficacy of Phenazopyridine with Nitrofurantoin in patients with Urinary tract infectioCTRI/2024/06/068294ANJU JOSHUA
尚未招募
3 期
To evaluate the benefits and side effects of garlic extract in the patients with mild hypertension who are under standard care of treatment.CTRI/2023/12/060512Sami Sabinsa Group Limited
已完成
不适用
A clinical trial to evaluate the safety and efficacy of Lycq® on subjects with high serum cholesterol levelsCTRI/2013/06/003786Edio Healthcare AB80